{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunotherapy+monotherapy&page=5", "query": { "intervention": "Immunotherapy monotherapy", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 210, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunotherapy+monotherapy&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunotherapy+monotherapy&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T21:51:25.421Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04428151", "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2020-08-06", "completion_date": "2025-10-30", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 55, "location_summary": "Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428151" }, { "nct_id": "NCT03837899", "title": "Durvalumab and Tremelimumab for Pediatric Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Cancer", "Solid Tumor Pediatric", "Hematological Malignancies" ], "interventions": [ { "name": "Durvalumab / Tremelimumab Combination Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 50, "start_date": "2019-03-07", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837899" }, { "nct_id": "NCT03911557", "title": "Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "Durvalumab and Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John L. Villano, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-06-08", "completion_date": "2025-10-10", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911557" }, { "nct_id": "NCT05549297", "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" }, { "name": "Tebentafusp with Pembrolizumab", "type": "DRUG" }, { "name": "Investigators Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2022-12-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549297" }, { "nct_id": "NCT03686124", "title": "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer" ], "interventions": [ { "name": "IMA203 Product", "type": "BIOLOGICAL" }, { "name": "IMA203 product- flat dose", "type": "BIOLOGICAL" }, { "name": "IMA203CD8 Product", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2019-05-14", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 13, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686124" }, { "nct_id": "NCT05635643", "title": "Study of CHS-114 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "CHS-114", "type": "DRUG" }, { "name": "toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2022-12-15", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 12, "location_summary": "Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635643" }, { "nct_id": "NCT05565378", "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2022-10-14", "completion_date": "2027-12-06", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 4, "location_summary": "Plantation, Florida • Albuquerque, New Mexico • Chattanooga, Tennessee + 1 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565378" }, { "nct_id": "NCT05716295", "title": "A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "MDK-703", "type": "DRUG" }, { "name": "Checkpoint Inhibitor, Immune", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medikine, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 26, "start_date": "2023-02-08", "completion_date": "2024-04-30", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 6, "location_summary": "Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05716295" }, { "nct_id": "NCT04374877", "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "CHS-388", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2020-04-22", "completion_date": "2025-06-05", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 18, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04374877" }, { "nct_id": "NCT07392957", "title": "Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "CTX-009", "type": "DRUG" }, { "name": "CTX-471", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2026-06-16", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-10T21:51:25.421Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07392957" } ] }